Efficacy of Pemetrexed Combined with Nedaplatin in Patients with Recurrent and Advanced Epithelial Ovarian Cancer
DENG Wen-jing
LIN Xiu-xin
ZHOU Ying
Abstract： Objective:To investigate the efficacy and side effects of pemetrexed in combination with nedaplatin in the treatment of patients with recurrent and advanced epithelial ovarian cancer.The primary objective was to determine the overall response rate (ORR),secondary objectives included progression-free survival (PFS) and toxicity.Method:Collecting recurrent 34 cases with advanced epithelial ovarian cancer patients,all patients were accepted nida,pemetrexed plus cisplatin chemotherapy:pemetrexed 500 mg/m2+saline 100 ml intravenous drip 10 min,30 min after intravenous drip of nida platinum 500 ml,80 mg/m2+saline water once every 21 d repeat.Result:All the patients were completed 2-6 routine chemotherapy,35.3%of the total response rate,sensitive platinum and platinum resistance groups ovarian response rate were 40.0%and 31.6%respectively,the more similar between the two groups has no statistical significance (P>0.05). Sensitive platinum and platinum resistance groups of PFS were 6.7 and 5.8 months,OS 12.7 and 10.4 months respectively.No drug related deaths,the main grade 3/4 adverse reaction as neutropenia (11.7%) and thrombocytopenia (5.9%).Conclusion:Pemetrexed plus nedaplatin is effective in patients with recurrent and advanced epithelial ovarian cancer,including platinum-sensitive and platinum-resistant ovarian cancer.The adverse effects are tolerable.
Keywords：Ovarian cancerPemetrexedNedaplatin
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 6-7,8 )